BioSpace News Archive

Core One Labs Inc. is pleased to announce it has entered into a letter of intent dated January 20, 2021 with Ketamine Infusion Centers of Texas, LLC, an arms-length-party, to review a potential acquisition of KICT.

Encision Inc., a medical device company owning patented Active Electrode Monitoring Technology that prevents dangerous stray electrosurgical burns in minimally invasive surgery, announced financial results for its fiscal 2021 third quarter that ended December 31, 2020.

With three additional COVID vaccine candidates close to being submitted for consideration for emergency approval by the FDA, AHF urges the Biden administration to aim high with its vaccine dosing goals—to distribute 5 million vaccine doses daily—for a better shot at achieving herd immunity more quickly

Inozyme Pharma, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton, announced the appointment of Deborah Wenkert, M.D. as senior vice president and chief medical officer, effective February 2, 2021.

Global health services company Cigna Corporation reported strong 2020 results driven by focused execution through the ongoing COVID-19 pandemic.

Vizient, Inc. announced it is again expanding the product portfolio for its Novaplus Enhanced Supply Program.

Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, February 18, 2021 at 5:00 pm eastern time to discuss the financial results for the fourth quarter and full year 2020, recent business developments, financial outlook for full year 2021, and revenue guidance for the first quarter of 2021.

Microbot Medical Inc. (Nasdaq: MBOT) has received official notification from the Japan Patent Office (JPO) that it intends to grant the Company a patent for its ‘One & Done’ guidewire technology for use with endoluminal interventions.

Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically improve the lives of patients with neurodegenerative diseases, announced today that it has received $11.6 million from the closing of the sale of Arvelle Therapeutics to Angelini Pharma.

Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its fourth quarter and full year 2020 financial results and operational highlights before open of U.S. markets on Thursday, March 4, 2021.